Excluding the impact of the one-time sale of patents last year, the company's revenues climbed 38 percent on strong product and service revenue growth.
The company is continuing to collect utility and cost effectiveness data for its SelectMDx test in reducing unnecessary procedures in men with signs of a possible prostate cancer.
The final LCD, which expands Medicare coverage of the firm's ConfirmMDx test to all providers, becomes effective on Sept. 3.
The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.
The firm said total test volumes rose 55 percent during the quarter, and test volumes for its SelectMDx liquid biopsy test nearly tripled in Europe.
The companies will co-fund a new study of the 3DS technology, and MDxHealth will have the option to exclusively license the telomere-based test.
The Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata research hospital in Rome will perform SelectMDx testing locally.
Excluding the sale of the company's colorectal cancer patents to Exact Sciences, its 2017 revenues rose 13 percent.
UgenTec will develop artificially intelligent software to support interpretation of MDxHealth's ConfirMDx and SelectMDx molecular prostate cancer tests.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.